Fig. 4. Cumulative rate of HBsAg loss/seroconversion and other dynamic changes in the blood serology of the cured and uncured children receiving antiviral therapy.

Comparison of dynamic changes in (A) cumulative rates of serum HBsAg loss and (B) seroconversion (log rank test, p<0.001, p<0.001, respectively), (C) serum HBsAg loads, and (D) anti-HBs levels (generalized estimating equation, p<0.001, p<0.001, respectively) in cured (n=18, orange line) vs. uncured (n=14, green line) children on antiviral therapy. Dotted lines in graphs C and D indicate the threshold cutoff value for HBsAg loss (<0.05 IU/mL or −1.3 log₁₀ IU/mL) and anti-HBs positivity (>1 log₁₀ IU/L or 10 IU/L). HBsAg, hepatitis B surface antigen.